The global insulin pumps market is projected to reach around USD 9,070 million by 2027, and North America led the market with the largest revenue share of around 46.7% in 2022, according to a study published.
Nemaura Medical today released its financial results for its Q1 2024 and provided a business update. The research and development expenses were $549,012 for the Q1 2024, compared $330,055 in Q1 2023. General and administrative expenses of the company reached to $1.5 milion during the first quarted of the financial year 2024, from $1.2 million in first quarter of the financial year 2023. Cash and cash equivalents at 30th June 2023 were reported approx. $4 million, and the Company announced on 11th of August, 2023 that it had secured a further $6.5m in clean debt.
The global Diabetes Care Devices market size is expected to reach USD 57.67 billion by 2030 and exhibit a CAGR of 8.7% in the forecast period (2023?2030), according to the latest research report from the publisher. The increasing prevalence of diabetes worldwide, growing awareness about diabetes management and the importance of regular monitoring, technological advancements in diabetes care devices, rising healthcare expenditure and favourable reimbursement policies fuel the market's growth.
DarioHealth announced a new agreement with PlanSource, a leading provider of cloud-based benefits administration and engagement technology, to offer integrated digital health solutions to more than 5 million consumers. The new agreement makes it easy for employers to select and implement Dario's integrated chronic condition management solutions to employee health benefit plans as part of a curated set of benefit solutions in the PlanSource Partner Marketplace. The integration of Dario's solutions into the PlanSource Marketplace creates a seamless digital pathway for employees to engage in solutions.
#institution
#dtx
#coaching
According to a new market research report titled "South Africa Diabetes Care Devices Market Report (2023-2028)," the market is estimated at USD 146.56 million in 2023. It is expected to register a CAGR of 4.08% during the forecast period. Players in the South African diabetes care devices market are focusing on technological innovations and advanced product development to help patients. The market is expected to witness growth in the coming years.
Liva is delighted to be selected as one of the leading digital therapeutics platforms to offer hybrid weight-loss programmes in partnership with the National Health Service (NHS). The National Institute for Health and Care Excellence (NICE) has published new guidance that will allow NHS patients to be referred to digital weight management services and prescribed weight-loss medication. Liva is one of four digital therapeutics platforms that have been approved to support patients throughout their treatment. These programmes, endorsed by the National Institute for Health and Care Excellence (NICE), leverage the potential of these digital platforms. Accessible through apps and computers, they enable healthcare specialists to provide comprehensive care and support online. Under the new scheme Liva will be able to prescribe weight-loss injections as part of the programme, a pivotal aspect of the treatment. These injections, such as semaglutide and liraglutide (known as Wegovy and Saxenda respectively), are accompanied by a reduced calorie diet and exercise plan.
#dtx
#coaching
Exercise can rapidly drop glucose in people with type 1 diabetes. Ubiquitous wearable fitness sensors are not integrated into automated insulin delivery (AID) systems. The researchers hypothesised that an AID can automate insulin adjustments using real-time wearable fitness data to reduce hypoglycaemia during exercise and free-living conditions compared with an AID not automating use of fitness data. Study population comprised of individuals (aged 21–50 years) with type 1 diabetes, who were enrolled into a 76 h single-centre, two-arm randomised (4-block randomisation), non-blinded crossover study to use an AID that detects exercise, prompts the user, and shuts off insulin during exercise using an exercise-aware adaptive proportional derivative (exAPD) algorithm or an AID that automates insulin adjustments using fitness data in real-time through an exercise-aware model predictive control (exMPC) algorithm. 27 participants (18 females) were enrolled into the study. Across the 76 h study, both algorithms achieved clinical time in range targets and time below range , significantly lower than run-in period. AIDs can integrate exercise data from smartwatches to inform insulin dosing and limit hypoglycaemia while improving glucose outcomes. Future AID systems that integrate exercise metrics from wearable fitness sensors may help people living with type 1 diabetes exercise safely by limiting hypoglycaemia.
#closed loop
Dana M Lewis, affiliated with the The Open Artificial Pancreas System project, has provided her commentary on the automated insulin delivery systems, in the Lancet Digital Health. She mentions that a challenge with any type of insulin delivery system is that once insulin is delivered, it cannot be removed from the body, and so improved ability to adjust and reduce insulin concentration in advance of or in response to physical activity is one area of opportunity for improving outcomes. The study by Peter Jacobs and colleagues suggests that it is possible to integrate activity data (ie, heart rate and accelerometer) from smart-watches into AID systems.
#closed loop
#cgm
Nemaura Medical, a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs, announces today that it has secured a further $6.5 million in non-dilutive funding though a clean debt facility with no warrants or convertible elements, from its existing lender. The company is also currently undertaking studies with the NHS (National Health Service) in the UK with its metabolic health program designed for the consumer market targeting obesity and pre-diabetes whilst refining its commercial offering in this space. Nemaura also continues to support its UK licensee with its application for reimbursement of sugarBEAT® in the UK.
Kakao Healthcare, the digital healthcare business of South Korean internet company Kakao Corporation, has partnered with Novo Nordisk to further develop its diabetes management service powered by mobile and AI technologies. According to a press release, Kakao Healthcare's digital diabetes management service, Project Gamma, will feature the French medical device company BIOCORP's Mallya smart sensor, which Novo Nordisk plans to release in South Korea some time this year. Its collaboration with Novo Nordisk followed its recent signing of a global partnership with Dexcom to set up a diabetes management service starting in South Korea later this year.
#connected device
#insulin pen
#cgm